Study of DONQ52 in Active Celiac Disease
← catalyst calendarNCT07239336 · readout in 300 d
Sponsored by Chugai Pharmaceutical (industry) · 4519.T — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
92estimated
Sites
74
Countries
Australia, New Zealand, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-12-16 | actual | When the study began enrolling |
| Primary completion | 2027-06-15 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-12-15 | estimated | The whole study's end, after follow-up |
| First posted | 2025-11-20 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Celiac Disease
Interventions
- Drug: Placebo DONQ52
- Dietary supplement: Simulated Inadvertent Gluten Exposure (SIGE) capsule
- Drug: DONQ52
- Dietary supplement: Simulated Inadvertent Gluten Exposure (SIGE) capsule
Primary outcome
what the primary-completion date above is the date OFChange in Villous Height to Crypt Depth Ratio (Vh:Cd)
measured Baseline to Week 27
Permalink · 4519.T's whole pipeline · Catalyst calendar · Every registered study · What changed